Friday, November 10, 2023 9:11:12 AM
Hamilton, Bermuda, Nov. 10, 2023 (GLOBE NEWSWIRE) --
November 10, 2023 -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced that it has received an “Intention to Grant” notice from the European Patent Office (EPO) for its patent application titled “Intranasal Composition Comprising Betahistine” (designated as European Patent 3698791).
The application is a continuation of the previously granted European Patent 3474850 and upon issuance, is expected to remain valid until February 2038. Combined, these two patents will provide key intellectual property protection for the Company's intranasal betahistine program (AM-125) in Europe. To date, the patent has been granted in around 50 countries worldwide, including key markets in North America and Europe. The allowed claims cover the composition of matter and methods of use for formulations of betahistine dihydrochloride for intranasal delivery.
“We are very pleased with the continued expansion of our patent portfolio covering the intranasal betahistine program,” commented Thomas Meyer, Altamira Therapeutics’ founder, Chairman and CEO. “Securing our intellectual property is pivotal as we strategically position our Company around our RNA delivery platform. With considerable interest from various parties, we anticipate collaborating with the appropriate partners to bring the AM-125 program to patients worldwide who are suffering from dizziness.”
About Betahistine
Betahistine, a small molecule structural analog of histamine, acts as an agonist at the H1 histamine receptor and as an antagonist at the H3 histamine receptor. Unlike histamine, it crosses the blood-brain-barrier. Betahistine is known to increase the release of histamine, acetylcholine, dopamine and norepinephrine in the brain. It increases cochlear, vestibular and cerebral blood flow and facilitates vestibular compensation and inhibits neuronal firing in the vestibular nuclei. Betahistine for oral administration is approved in about 115 countries (with the U.S. being a notable exception) for the treatment of vertigo and Meniere’s disease. Despite its good safety profile, the clinical utility of orally administered Betahistine is limited due to poor bioavailability.
About AM-125
AM-125 is an intranasal formulation of betahistine. Because of its ability to circumvent first-pass metabolism, AM-125 has been shown to have 5-to-29 times higher bioavailability than orally administered betahistine. Altamira is developing AM-125 for the treatment of acute vestibular syndrome which may be triggered by a variety of causes including trauma, infection, or inner ear fluid disturbances. With its incidence and prevalence increasing with age, vestibular dysfunction affects more than one third of the U.S. population 40 years of age and older.
About Altamira Therapeutics
Altamira (Nasdaq:CYTO) is dedicated to developing RNA-based therapeutics for extrahepatic tar-gets (OligoPhore™ / SemaPhore™ delivery platforms). The Company currently has two flagship siRNA programs in preclinical development beyond in vivo proof of concept: AM-401 for KRAS driven cancer and AM-411 for rheumatoid arthritis. The versatile delivery platform is also suited for mRNA and other types of RNA therapeutics and is planned to be leveraged via out-licensing to pharma or biotech companies. In addition, Altamira is in the process of divesting and/or out-licensing its legacy assets in allergology and viral infection (Bentrio® OTC nasal spray; commercial) and inner ear therapeutics (AM-125 nasal spray for vertigo; post Phase 2; Keyzilen® and Sonsuvi® for tinnitus and hearing loss; Phase 3). Founded in 2003, Altamira is headquartered in Hamilton, Bermuda, with its main operations in Basel, Switzerland. For more information, visit: https://altamiratherapeutics.com/
Forward-Looking Statements
Recent CYTO News
- Altamira Therapeutics Provides Business Update • GlobeNewswire Inc. • 05/28/2024 02:31:08 PM
- Altamira Therapeutics Announces Dissemination of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis Through Social Media Channels of Top Allergy Journal • GlobeNewswire Inc. • 05/23/2024 12:47:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/16/2024 08:15:32 PM
- Altamira Therapeutics Announces Filing of Provisional Patent Application for OligoPhore Nanoparticles with siRNA Targeting p65 Protein in Treatment of Cancer and Inflammation • GlobeNewswire Inc. • 05/01/2024 12:47:00 PM
- Altamira Therapeutics Announces Publication of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis in Top Peer Reviewed Journal • GlobeNewswire Inc. • 04/24/2024 12:47:00 PM
- Altamira Therapeutics Provides Business Update, Reports Full Year 2023 Financial Results • GlobeNewswire Inc. • 04/10/2024 12:00:00 PM
- Altamira Therapeutics to Host Full Year 2023 Financial Results and Business Update Call on April 10, 2024 • GlobeNewswire Inc. • 04/04/2024 12:45:00 PM
- Altamira Therapeutics Announces Collaboration with Univercells Group on Nanoparticle-Delivered mRNA Vaccines • GlobeNewswire Inc. • 03/25/2024 12:47:00 PM
- Altamira Therapeutics’ Peptide-Based Delivery Platform Shown to Enhance Potency of Commonly Used Gene Delivery Method as Published in Peer-Reviewed Journal • GlobeNewswire Inc. • 02/07/2024 01:47:00 PM
- Altamira Therapeutics Files Second Provisional Patent Application for OligoPhore Nanoparticles Targeting Different KRAS Mutations in Cancer Treatment • GlobeNewswire Inc. • 01/24/2024 01:47:00 PM
- Form 424B4 - Prospectus [Rule 424(b)(4)] • Edgar (US Regulatory) • 01/22/2024 10:02:55 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 01/22/2024 05:15:31 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/19/2024 09:45:26 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 01/19/2024 09:40:50 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/19/2024 09:30:47 PM
- Form F-3 - Registration statement by foreign private issuers • Edgar (US Regulatory) • 01/08/2024 10:02:56 PM
- Altamira Therapeutics to Present at 3rd Annual mRNA-Based Therapeutics Summit • GlobeNewswire Inc. • 01/08/2024 01:47:00 PM
- Altamira Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement • GlobeNewswire Inc. • 12/29/2023 01:47:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/11/2023 01:01:04 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/11/2023 01:00:31 PM
- Altamira Therapeutics Provides Investor and Business Update • GlobeNewswire Inc. • 12/11/2023 01:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/08/2023 02:00:02 PM
- Altamira Therapeutics to Host Investor & Business Update Call on December 11th • GlobeNewswire Inc. • 12/05/2023 05:54:05 PM
- Altamira Therapeutics Regains Compliance with Nasdaq Minimum Stockholders' Equity Requirement • GlobeNewswire Inc. • 11/29/2023 03:20:05 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/22/2023 09:30:39 PM
FEATURED DaBaby and Stunna 4 Vegas's "NO DRIBBLE" Joins Music Licensing, Inc.'s Portfolio • Jun 7, 2024 10:15 AM
Mushrooms Inc. (OTC: MSRM) Announces Significant Share Buy Back by the Board Director and New Strategic Initiatives. • MSRM • Jun 5, 2024 1:32 PM
Hydromer Announces Launch of HydroThrombX Medical Device Coating Technology • HYDI • Jun 5, 2024 10:24 AM
Dr. Michael Dent Finances $1 Million to Drive HealthLynked's Healthcare Transformation • HLYK • Jun 5, 2024 8:00 AM
Avant Technologies Enters Binding LOI to Purchase Dozens of High-Performance, Immersible, AI-Powered Servers • AVAI • Jun 5, 2024 8:00 AM
IQST - iQSTEL Announces $290 Million 2024 Annual Revenue Forecast • IQST • Jun 4, 2024 1:43 PM